Increased plasma DYRK1A with aging may protect against neurodegenerative diseases
Authors:
- Jean-Maurice DelabarJDJean-Maurice Delabar
- Julien LagardeJLJulien Lagarde
- Marta FructuosoMFMarta Fructuoso
- Ammara MohammadAMAmmara Mohammad
- Michel BottlaenderMBMichel Bottlaender
- Eric DoranEDEric Doran
- Frederic SchmittFSFrederic Schmitt
- Elisabeth HeadEHElisabeth Head
- Marie SarazinMSMarie Sarazin
- Marie-Claude PotierMPMarie-Claude Potier
Preprint
- 4 January 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Early markers are needed for more effective prevention of Alzheimer's disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before cognitive decline, reflecting increased risk for AD.Keywords
All Related Versions
- Version 1, 2023-01-04, Research Square
- Published version: Translational Psychiatry, 13 (1), 1.
This publication has 42 references indexed in Scilit:
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down SyndromeJournal of Neuropathology & Experimental Neurology, 2011
- Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1ANature Communications, 2010
- Neuropathology of Alzheimer's DiseaseMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone HomeostasisJournal of Biological Chemistry, 2009
- Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1APLOS ONE, 2009
- Classification of Human Chromosome 21 Gene-Expression Variations in Down Syndrome: Impact on Disease PhenotypesThe American Journal of Human Genetics, 2007
- Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic modelsNeurobiology of Disease, 2005
- Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR)Journal of Intellectual Disability Research, 1996